Hepatitis Research Today is a free monthly online journal that collates and summarizes the latest research about Hepatitis, including details on hepatitis a, b, c, causes, symptoms.

Volume 3 (2008), Issue 2 (February)

1. Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C.
   Clin Gastroenterol Hepatol, 6(2): 234-41. [Abstract] [Full-text]
2. Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C.
   Clin Gastroenterol Hepatol, 6(2): 242-7. [Abstract] [Full-text]
3. Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C.
   Gastroenterology, 134(2): 432-9. [Abstract] [Full-text]
4. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach.
   Gastroenterology, 134(2): 405-15. [Abstract] [Full-text]
5. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis.
   Gastroenterology, 134(2): 416-23. [Abstract] [Full-text]
6. Performance characteristics of microparticle enzyme and chemiluminescence immunoassays for measurement of anti-HBc immunoglobulin M in sera of patients with HBeAg-negative chronic hepatitis B virus infection.
   Clin Vaccine Immunol, 15(2): 385-7. [Abstract] [Full-text]
7. Seroepidemiology of hepatitis A in voluntary blood donors from Pune, western India (2002 and 2004-2005).
   Epidemiol Infect, 136(3): 406-9. [Abstract] [Full-text]
8. Estimating the impact of vaccination using age-time-dependent incidence rates of hepatitis B.
   Epidemiol Infect, 136(3): 341-51. [Abstract] [Full-text]
9. Differences in the social networks of ethnic Vietnamese and non-Vietnamese injecting drug users and their implications for blood-borne virus transmission.
   Epidemiol Infect, 136(3): 410-6. [Abstract] [Full-text]
10. Use of sensitivity analysis to assess the effects on anti-hepatitis A virus antibodies of access to household water supply.
    Epidemiol Infect, 136(3): 334-40. [Abstract] [Full-text]
11. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B.
    Hepatology, 47(2): 428-34. [Abstract] [Full-text]
12. Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis.
    Hepatology, 47(2): 581-91. [Abstract] [Full-text]
13. CD161 expression on hepatitis C virus-specific CD8+ T cells suggests a distinct pathway of T cell differentiation.
    Hepatology, 47(2): 396-406. [Abstract] [Full-text]
14. Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial.
    Hepatology, 47(2): 605-12. [Abstract] [Full-text]
15. Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage.
    Hepatology, 47(2): 592-5. [Abstract] [Full-text]
16. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus.
    Hepatology, 47(2): 407-17. [Abstract] [Full-text]
17. Acute viral hepatitis increases liver stiffness values measured by transient elastography.
    Hepatology, 47(2): 380-4. [Abstract] [Full-text]
18. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.
    Hepatology, 47(2): 447-54. [Abstract] [Full-text]
19. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers.
    Hepatology, 47(2): 455-60. [Abstract] [Full-text]
20. Diacylglycerol acyltranferase 1 anti-sense oligonucleotides reduce hepatic fibrosis in mice with nonalcoholic steatohepatitis.
    Hepatology, 47(2): 625-35. [Abstract] [Full-text]
21. Pseudohyponatremia in a patient with HIV and hepatitis C coinfection.
    J Gen Intern Med, 23(2): 202-5. [Abstract] [Full-text]
22. Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors.
    Clin Infect Dis, 46(5): 768-74. [Abstract] [Full-text]
23. Antibody-dependent enhancement of hepatitis C virus infection.
    J Virol, 82(5): 2140-9. [Abstract] [Full-text]
24. CD4 T cells contribute to virus control and pathology following central nervous system infection with neurotropic mouse hepatitis virus.
    J Virol, 82(5): 2130-9. [Abstract] [Full-text]
25. Communicating about alcohol consumption to nonharmful drinkers with hepatitis C: patient and provider perspectives.
    J Gen Intern Med, 23(3): 242-7. [Abstract] [Full-text]
26. Evaluation of pathways for release of Rift Valley fever virus into domestic ruminant livestock, ruminant wildlife, and human populations in the continental United States.
    J Am Vet Med Assoc, 232(4): 514-29. [Abstract] [Full-text]
27. Hepatitis E virus and chronic hepatitis in organ-transplant recipients.
    N Engl J Med, 358(8): 811-7. [Abstract] [Full-text]
28. Hepatic steatosis in Iranian patients with chronic hepatitis C.
    Med Princ Pract, 17(2): 126-30. [Abstract] [Full-text]
29. Acute hepatitis B 14 years after the implementation of universal vaccination in Italy: areas of improvement and emerging challenges.
    Clin Infect Dis, 46(6): 868-75. [Abstract] [Full-text]
30. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection.
    Lancet Infect Dis, 8(3): 167-78. [Abstract] [Full-text]
31. NOD2: a potential target for regulating liver injury.
    Lab Invest, 88(3): 318-27. [Abstract] [Full-text]
32. Hepatitis C infection and risk of malignant lymphoma.
    Int J Cancer, 122(8): 1885-90. [Abstract] [Full-text]
33. Human uridine-cytidine kinase phosphorylation of ribavirin: a convenient method for activation of ribavirin for conjugation to proteins.
    J Biomed Sci, 15(2): 205-13. [Abstract] [Full-text]
34. Hepatitis B and C virus infection and the risk of biliary tract cancer: a population-based study in China.
    Int J Cancer, 122(8): 1849-53. [Abstract] [Full-text]
35. Hepatitis B viral factors and clinical outcomes of chronic hepatitis B.
    J Biomed Sci, 15(2): 137-45. [Abstract] [Full-text]
36. Increased cytotoxic T-lymphocyte epitope variant cross-recognition and functional avidity are associated with hepatitis C virus clearance.
    J Virol, 82(6): 3147-53. [Abstract] [Full-text]
37. NKG2D receptor signaling enhances cytolytic activity by virus-specific CD8+ T cells: evidence for a protective role in virus-induced encephalitis.
    J Virol, 82(6): 3031-44. [Abstract] [Full-text]
38. Virus-specific T-cell immunity correlates with control of GB virus B infection in marmosets.
    J Virol, 82(6): 3054-60. [Abstract] [Full-text]
39. Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis.
    Aliment Pharmacol Ther, 27(7): 542-51. [Abstract] [Full-text]
40. Quantification of intrahepatic total hepatitis B virus DNA in chronic hepatitis B patients and its relationship with liver histology.
    J Clin Pathol, 61(3): 338-42. [Abstract] [Full-text]
41. Antinuclear antibody is associated with a more advanced fibrosis and lower RNA levels of hepatitis C virus in patients with chronic hepatitis C.
    J Clin Pathol, 61(3): 333-7. [Abstract] [Full-text]
42. Reversible oxacillin-associated hepatitis in a 9-month-old boy.
    J Paediatr Child Health, 44(3): 146-8. [Abstract] [Full-text]
43. Intermediate-term outcomes of hepatitis C-positive compared with hepatitis C-negative deceased-donor renal allograft recipients.
    Am J Surg, 195(3): 298-302; discussion 302-3. [Abstract] [Full-text]
44. Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon.
    J Viral Hepat, 15(4): 314-21. [Abstract] [Full-text]
45. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
    J Viral Hepat, 15(4): 300-4. [Abstract] [Full-text]
46. Economic impact of extended treatment with peginterferon alpha-2a and ribavirin for slow hepatitis C virologic responders.
    J Viral Hepat, 15(4): 293-9. [Abstract] [Full-text]
47. Severe weight loss in HIV / HCV-coinfected patients treated with interferon plus ribavirin: incidence and risk factors.
    J Viral Hepat, 15(4): 255-60. [Abstract] [Full-text]
48. Monitoring SCCA-IgM complexes in serum predicts liver disease progression in patients with chronic hepatitis.
    J Viral Hepat, 15(4): 246-9. [Abstract] [Full-text]
49. Risk of hepatitis C virus transmission through drug preparation equipment: a systematic and methodological review.
    J Viral Hepat, 15(4): 279-92. [Abstract] [Full-text]
50. Increasing the uptake of hepatitis C virus testing among injecting drug users in specialist drug treatment and prison settings by using dried blood spots for diagnostic testing: a cluster randomized controlled trial.
    J Viral Hepat, 15(4): 250-4. [Abstract] [Full-text]
51. Response rates to combination therapy for chronic HCV infection in a clinical setting and derivation of probability tables for individual patient management.
    J Viral Hepat, 15(4): 271-8. [Abstract] [Full-text]
52. Substitution rate of the hepatitis B virus surface gene.
    J Viral Hepat, 15(4): 239-45. [Abstract] [Full-text]

© 2006-2008 Hepatitis Research Today. All Rights Reserved.